FDA requires more data from Kips Bay for eSVS Mesh; Aethlon announces HER2osome launch;

> The FDA is requiring additional information from Kips Bay Medical ($KIPS) before allowing the company to pursue a clinical study of the eSVS Mesh in the U.S., according to the firms Chairman and CEO Manny Villafaña. The agency has told Kips Bay it does not believe that the company has provided sufficient data yet to support the request for an IDE. Kips Bay release

> Aethlon Medical has reported the introduction of HER2osome, a novel medical device strategy to inhibit the progression of HER2+ breast cancer. Aethlon release

> STENTYS has enrolled the 500-patient target of the international APPOSITION III study for its self-apposing stent. STENTYS release

> Medtronic ($MDT) is slated to appear before the FDA's circulatory systems advisory panel Oct. 27 for a review of its PMA for the Ablation Frontiers cardiac ablation system. Story

> The Society of Interventional Radiology Foundation's Discovery Campaign has won a $100,000 pledge from the St. Jude Medical Foundation, the philanthropic arm of St. Jude Medical ($STJ). SIR release

> GE Healthcare ($GE) has obtained clearance of its Veo CT image reconstruction technology, which promises to provide high resolution tomography scans with reduced radiation doses. Article

And Finally... Watson, the IBM supercomputer that appeared on "Jeopardy!," is working in the field of medicine. A version of the game-show champion could appear in examination rooms, offering assistance to doctors. Item